

20th January 2026

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400001

Scrip Code: BSE – AJANTPHARM 532331

National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no.
C/1, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051

Scrip Code: NSE AJANTPHARM EQ

Ref.: Clarification on News Item Appearing in Reuters- Intimation under Regulation 30(11) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs/Madam,

This is with reference to a news article appeared in various publications such as Reuters, Economic Times, Business Standards, etc online edition on January 19, 2026, titled “Everstone to sell stake in India's Burger King operator Restaurant Brands Asia, sources say”, which inter alia mentions that “*it was not immediately clear what stake Ajanta would take in the company*”.

In this regard, we would like to clarify that neither Ajanta Pharma Limited nor its Management is party to, and involved in, the transaction referred to in the said news article.

The Company or its Management has not entered into, discussed, negotiated, or considered any proposal relating to the acquisition of any stake in Restaurant Brands Asia or any Burger King franchise entity.

Accordingly, the reference to Ajanta Pharma Limited in the said news article is incorrect and does not relate to the Company. The Company also denies the rumours and speculation circulating on social media in this regard.

Ajanta Pharma Limited continues to adhere to the highest standards of corporate governance and disclosure. Any material information requiring disclosure under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be appropriately and promptly communicated to the Stock Exchanges.

We request you to take the above clarification on record.

Thanking you,

Yours faithfully,

Gaurang Shah
Sr. VP – Legal & Company Secretary